Carna Tech Note No.1 : Production of Highly Active Protein Kinases for Drug Discovery Applications

9/ 9/21

Carna Biosciences’ long standing commitment to manufacture highly active protein kinases is based on our belief that drugs designed to inhibit
disease related protein dysregulation should be evaluated in activity- based enzyme assays using the most active kinases. Production of protein
kinases meeting these standards is not always an easy task. Despite use of stable Escherichia coli or insect cell expression systems, the result can be
production of kinases with little or no detectable activity. Here we’ d like to share how Carna produces the high quality kinases on which our
reputation is built. Are the intracellular kinases present in living cells
always active? What about receptor tyrosine kinases, which generally become active only if stimulated by growth factors or other binding
proteins? What about kinases such as MAPKs that are activated by phosphorylation by upstream kinases? Other kinase family members require
complex formation for activity, for example the CDKs, where the kinases must form a complex with a cyclin expressed in a cell cycle-dependent
manner for activation. By replicating these natural phenomena as precisely as possible, active recombinant kinases are produced. Below we
outline the methods we deploy to produce highly active kinases.

Pre-incubation of kinases with ATP
Many receptor-type tyrosine and other kinases expressed in cells are activated by agonist stimulation. However, isolating membrane proteins from our kinase expression systems is not easy. Instead, we express only the
intracellular domain of the receptor tyrosine kinase, then incubate in the presence of ATP to promote autophosphorylation. This results in the
kinase being fully phosphorylated and increasing its activity following purification. This method is employed in production of some kinases at Carna.

Use of upstream kinases
To produce kinases involved in a phosphorylation cascade (a sequence of signaling pathway events where one enzyme is phosphorylated by upstream
kinases, such as the MAPK cascade), we use an insect cell co-expression system with the kinase of interest plus upstream kinase. We then purify
based on tag differences to yield an activated target kinase (see Figure 1).

Fig.1 (A) LIMK phosphorylated by Rock phosphorylates cofilin, inducing actin cytoskeleton rearrangement. (B) LIMK production w/ and w/o an upstream kinase (C) Kinase activity from each production
Fig.1
(A) LIMK phosphorylated by Rock phosphorylates cofilin, inducing actin cytoskeleton rearrangement.
(B) LIMK production w/ and w/o an upstream kinase
(C) Kinase activity from each production
An alternative, simpler method involves incubating a purified target kinase with an upstream kinase in the presence of ATP, then re-purifying it to remove the upstream kinase, resulting in an active form of the kinase of interest (Fig. 2).
Fig. 2.
Fig. 2.
(A) For maximal activation of JNK, Thr and Tyr of the Thr-Pro-Tyr motif must be phosphorylated by MAP2K4 and MAP2K7.
(B) Carna mixes GST-JNK with His-MAP2K4 and His-MAP2K7 then re-purifies GST-JNK.
(C) Activity comparison                                                                                           
 
Protease cleavage of Expression Tag
Artificial manufacturing of protein kinases comes with a risk of inactivating the kinase activity. In general, Carna preferentially uses a GST tag to express kinases. Given that GST is a 26kDa protein that can dimerize, it’ s difficult to say that this tag has no effect on the activity of the protein. As one solution, we incorporate a PreScission Protease (cytiva) cleavage site in our GST fusion kinases. Excising the GST tag from the protein can increase the activity of some
kinases, as shown with our TSSK kinase below as an example (Fig. 3).
Fig.3 PreScission protease treatment of GST-TSSK increases kinase activity.     
       
Dephosphorylation
GSK3 is an example o f a kinase where phosphorylation of certain sites leads to lower rather than greater kinase activity. Specifically, it has been reported that Ser21 (GSK3a) or Ser9 (GSK3b) phosphorylation leads to inactivation of the kinase. By implementing enzymatic treatment with phosphatase, GSK3 activity can be regained (Fig. 4).
Fig.4 Kinase Activity regained by treating GST-GSK3 kinase with phosphatase.
No phosphatase activity was detected in the final product.
Utilizing the various approaches and treatments outlined above, in combination with our extensive kinase knowledge and experience, Carna has a long history of producing highly active kinases. We employ an approach optimized
for each specific kinase, enabling us to consistently deliver enzymes of superior quality. Each kinase we sell is accompanied with a product information sheet describing the details of the enzyme. Please visit our website or contact
us for additional details.
Did you know that Carna’ s kinase profiling services exclusively utilize the same high quality kinases we produce in-house?

Leave a comment